Cel
The last decade's basic and clinical oncology research has revealed a number of so far unrecognised regulating responses (e.g. HIF-1) in cells exposed to hypoxia. These processes have been proven highly important for embryonic development and survival and seem to have a major impact on tumour progression and resistance to radiotherapy and certain types of chemotherapy. Because of their strong over-expression in solid cancer tumours in comparison to adjacent normal tissue of these processes, this new knowledge may open a therapeutic window for cancer treatment by utilising hypoxia-responsive processes as drug targets.
Major EU stakeholders in academic research and industry will therefore explore and validate these new molecular targets as a necessary step in the preclinical development of innovative new diagnostics and treatment.
Our committee has identified the outstanding basic problems to be solved over the first 2 to 3 years in order to allow a successful drug development. These include: dissection of relevant steps in cancer cell response to hypoxia, development of the technology platform needed, further identification and characterisation ofmarker/target molecules, and initial in vitro drug development. Our own mid-term evaluation will then select which hypoxic processes may be suitable as targets for cancer-specific treatment.
Simultaneously, we will study diagnostic tagging and therapeutic strategies leading up to a selection process of promising compounds to be further developed after the end of the project period. The new treatments will be developed along two lines: targeting known cytostatics towards the newly discovered hypoxia-responsive molecules and searching for so far unused compounds, preferably toxic to pathways active during hypoxia. The final effort will be to ensure continued (EU) industry utilisation of our results.
Dziedzina nauki
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesdevelopmental biology
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesmolecular biology
Słowa kluczowe
Zaproszenie do składania wniosków
FP6-2002-LIFESCIHEALTH
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
IP - Integrated ProjectKoordynator
AALBORG
Dania
Zobacz na mapie
Uczestnicy (25)
LONDON
Zobacz na mapie
VITRY SUR SEINE
Zobacz na mapie
OXFORD
Zobacz na mapie
ERLANGEN
Zobacz na mapie
LONDON
Zobacz na mapie
STOCKHOLM
Zobacz na mapie